Genocea Biosciences Inc., of Cambridge, Mass., presented preclinical data at the Society for Immunotherapy of Cancer meeting in Washington suggesting potential deleterious effects of inhibitory neoantigens because of their association with inhibition of T-cell responses to tumors.